On 17 April 2013, on the premises of the French Trade Commission UBIFRANCE in central London, three executives from Boiron, in France, gave a press conference concerning Camilia®, the homeopathic medicine for treating teething pains in babies and young children that is being launched in the UK.
You will find, below, the full text of the three speakers’ interventions. Further details are available on request, and interviews can be arranged face to face or over the telephone (depending on the schedule of the three executives concerned).
For the Power Point of the presentation that was given during the press conference, on 17 April, here in London, please click here:http://www.ubifrance.com/medias/document/boiron-press-conference_19_4_2013_43_10.pdf
Should you wish to have any further information, please contact Ms Katherine Woods, Press Officer, on 0207-024-3612 or firstname.lastname@example.org.
Profile of Speakers at the Press Conference held on 18 April 2013 in London (UK)
Dr Laurence Terzan is the Medical Director at Boiron. Dr Terzan is an epidemiologist with a Diplôme National de Santé Publique (France’s National Public Health Diploma) as well as qualifications from Centre d’Enseignement et de Développement de l’Homéopathie (the Centre for the Teaching and Development of Homeopathy) that she earned in 1994 and 1998 respectively.
Mr Jérôme Delannoy is Export Manager of Boiron: a trained veterinary surgeon, he has worked in the pharmaceutical industry for 25 years. He began his career in the animal-health sector, which led him to live in Southern Africa and, then, to travel worldwide. Mr Delannoy next worked in various human-health pharmaceutical laboratories. Since 2004, he has been Regional Director for Boiron, managing business operations in the UK, in addition to other countries.
Mr Jean-François Lurol is Director of External Relations at Boiron. He studied at the Ecole Française des Attachés de Presse (France’s School for Press Officers) in Lyons (South-Eastern France), and is now a member of the Club de Presse de Lyon (Lyons’ Press Club) and of the Syndicat National des Attachés de Presse (France’s National Press Officers’ Union).
Mr J F Lurol, Director of External Relations at Boiron: An overview of Boiron and Camilia®
“Good morning, Ladies and Gentlemen,
“I am Jean-François Lurol, Director of External Relations at Boiron laboratories.
“I am very happy to be here for this press conference. Thank you for coming and, most importantly, please excuse my terrible French accent!
“In England, scepticism is important regarding homeopathy. You probably know this. We cannot leave things the way they are. Homeopathy is a therapy. It has been part of medicine for 200 years and it is very helpful to patients and health professionals. Our medicines [at Boiron] are efficacious and they are used daily by millions of people. They are safe and present no health risk. Boiron’s responsibility is to make this reality known.
“That is the reason why we have an R&D programme. Our medicines are assets for public health and we want to pass this message on to everyone. So, we are here to talk about the launch of our medication — Camilia®. For us, this is a great novelty. Indeed, Camilia® is the first medication that we distribute in the UK.
“I will not say any more about Camilia®. My colleagues will do a better job of it than I would. Now, I would like to introduce them to you. I will start with Mr Jérôme Delannoy, Export Manager. He will tell you why and how we are launching this medication across the UK.
“I would also like to introduce you to our Medical Director, head of our research department, Dr Laurence Terzan. She will talk about teething pains in infants and the possibilities offered by a homeopathic medicine such as Camilia®.
“Following these presentations, we’ll be pleased to answer your questions. Before handing over to Jérôme Delannoy, I would like to talk shortly about Boiron.
“Our company, Boiron, was created 100 years ago. Jean and Henri Boiron, the company’s founders, were scientists and developers at heart. Nowadays, Boiron remains an independent, family-run laboratory — this is an exception in the international pharmaceutical field. Christian Boiron, the son of Jean Boiron, is the company’s General Manager.
“The company’s independence means that Boiron is driven by (and makes) its own strategic choices. Boiron provides useful and safe medications for health professionals and the general public. It contributes to public health.
“Today, the group is present in nearly 60 countries and continues the work of its founders, who were pioneers in the development of homeopathic medications worldwide.
“In 2012, Boiron had a turnover of £480 million and employed 3,900 staff. The company is headquartered in Lyons (in South-Eastern France) and has a representative in London (UK).
“Thank you for your attention. I will give the floor to Jérôme Delannoy.”
Mr Jérôme Delannoy, Export Manager, about the launch of Camilia® in the UK
“Good morning Ladies and Gentlemen,
“I am delighted to welcome you here today for the launch of our new product, Camilia® Oral Solution.
“This is a very important event for our company, as it is our first OTC product to be marketed in the UK.
“We have several reasons to be satisfied, as I will explain.
“Firstly, in relation to the Marketing Authorisation we have secured: Camilia® is a pharmaceutical product and we have been granted a Marketing Authorisation two years only after submission to the Ministry of Health [in the UK]. This may sound like a long time but, indeed, this is rather short for a pharmaceutical-product assessment.
“If the assessment went so quickly, this is due to the quality of the medical information provided in our technical files submitted to the MHRA, which delivers Marketing Authorisations [in Britain].
“Secondly, we are proud to launch a product which brings a simple, efficacious and healthy solution to teething pains in babies and toddlers. This product will improve the quality of life of these children but, also, of their parents!
“Let me, now, give you a few details about Camilia®.
“First of all, what is Camilia® Oral Solution, and what is it used for?
“Camilia® Oral Solution is a homeopathic medicinal product used within the homeopathic tradition for the relief of teething pain and other minor symptoms associated with teething in babies and toddlers.
“Second, how to administer Camilia® Oral Solution?
“Regarding the dosage, Camilia® Oral Solution is suitable for use by babies aged between one month and two years, and young children aged between two and six years.
“The usual dose is the contents of a single-dose unit, two to three times a day. This solution is for oral use only.
“As for the duration of the treatment, this medicine should not be used for more than three days. If symptoms worsen or persist after three days, a doctor or qualified healthcare practitioner should be consulted.
“In a few moments, Dr Laurence Terzan will give you more medical details about Camilia®. Nevertheless, I would like to insist on a few product characteristics [as follows].
“No1, the efficacy of Camilia® has been reported by many parents.
“No2, Camilia® is safe because it is free of lactose, ethanol, flavourings or preservatives.
“No3, Camilia® is easy to use because it consists of [a dose of] 1ml of liquid to pour into the baby’s mouth, and the product has no taste [which reduces risks of rejection by the baby].
“No4, Camilia® is ready to use: there is no need to dilute a powder.
“No5, Camilia® is a hygienically safe product, because the single-dose containers are sterile and protected by an aluminium foil sachet. Thus, it is also easy to carry along [when parents are on the move with their baby].
“Since we are talking about teething in babies, you know that children love stories. Do you know that Camilia® already has a nice story to tell? Our product is manufactured in France, near Euro Disney [i.e. Disneyland® Paris]…but Camilia® was not born in France. The product was first marketed in Canada, in 1994.
“Since then, Boiron has launched Camilia® in several countries: France, the USA, Canada, Russia, Switzerland, Tunisia, Poland…and, everywhere, Camilia® has achieved huge success amongst members of the public. For example, last year , in France, an average of five boxes of Camilia® were sold per new-born baby.
“More recently, and to satisfy market demand, we have launched larger pack sizes, such as boxes with 20 or 30 single-dose containers. This will, hopefully, also happen later in the UK.
“Camilia® will be available from 1st May 2013 onwards in London, but also in the rest of the UK.
“Our product is stocked and distributed by Alliance Healthcare. Thus, Camilia® could be bought or ordered from any pharmacy, even if we have a closer partnership with the Alphega pharmacies.“We are also implementing a two-stage communication plan.
“First of all, towards healthcare professionals and, more particularly, pharmacists, midwives, and health visitors: parents will be able to seek advice from these professionals.
“Also, directly to potential users: communication tools will be available at points of sale. Advertisements will be placed in the major parenting magazines.
“A website is also under construction to supply updated information on Camilia®. It will also include a pharmacy locator to find the nearest retail point. The recommended retail price for Camilia®, at launch, is £6.95 per standard-size pack [in the UK].
“We are all very excited about this first launch and we hope that more Boiron products will follow soon. And, now, I will hand over to our medical director, Dr Laurence Terzan.
”Dr Laurence Terzan, Medical Director of Boiron, about Camilia®’s medical properties and proven effectiveness
“It is a pleasure for me to meet you, and share with you some information about Camilia®.
“I am the Medical Director of the Research Division of Laboratoire Boiron, in France.
“Today, I will present to you our medicine, Camilia®, and some results about Camilia® in relation to teething symptoms, through a study we have carried out.
“First of all, Camilia® is a homeopathic medicine that is indicated in the teething of babies. Camilia® has a therapeutic impact on both general and local symptoms. It acts fast to relieve the symptoms [of teething].
“Camilia® is made from natural plants [as follows].
“Calendula officinalis, also known as the English marigold, possesses antiseptic as well as anti-inflammatory properties. It is used in dermatology and stomatology. Chamomilla Vulgaris, for its part, is indicated for teething. It will relieve gingival and dental pain and alleviate fever. Furthermore, as it has sedative properties, it will lessen the baby’s irritability.
“Phytolacca decandra, commonly known as Poke Root, is a herb. It is used for the treatment of pharyngitis, gingivitis and sore throat, which can accompany teething.
“Rheum officinale is a medicine made out of a plant — rhubarb roots. This medicine is indicated for the treatment of abdominal pain, including soft saddles and diarrhoea, as induced by teething.
“One important point to highlight is that Camilia® has no side effects, and this is a key advantage, especially to parents.
“The presentation of Camilia® as a single dose is safe. It can be associated to gels when the symptoms are marked.
“Teething is a natural occurrence in childhood, usually beginning at around four months and continuing until the age of two years.
“However, teething symptoms are not really described in the medical literature as they are not considered to be a medical complaint: there is no existing consensus regarding the symptoms attributable to teeth development and there are no guidelines for their treatment. Teething-symptoms management is a recurrent concern in paediatric practice.
“Let me briefly present to you the study we carried out about Camilia®.
“First of all, the aim of the study: it was to describe teething symptoms and evaluate their management by paediatricians with the help of Camilia® (our homeopathic medicinal product) and Delabarre® as well as Dolodent® (which are gingival gels): all are common treatments indicated, in real-life medical practice [for teething problems in young children].
“Second, the method that we used: this prospective, observational study involved 161 French paediatricians, who agreed to participate and filled out case reports for the first four children aged three to 24 months that they treated for teething.
“Medical and treatment dates were collected at baseline and at seven days, if a follow-up was necessary.
“In parallel, parents were asked to fill out a diary to list symptoms and delivered treatments daily, and to enter details of their level of satisfaction [in view of the treatment and its outcomes] on Day 7.
“And now, the results: the data concerning 597 children at baseline and [contained in] 426 questionnaires was analysed.
“The median age was eight months, 58.50% [of children] were male, and it was the first teething experience for 49.80% of them.
“The mean number of symptoms observed by the paediatricians at the inclusion visit was 4.90. Overall, 96.60 % of children had at least one oral-care/oral-hygiene symptom and 94.30% developed at least one systemic symptom.
“The oral-hygiene symptoms included gum tumefaction, salivation and rashes.
“The systemic symptoms were excitability and irritability; unusual crying; sleep disorders; nappy rashes; soft saddles; diarrhoea; and, finally, bouts of fever.
“A total of 71.20% of the children were prescribed Camilia®: for half of them, it was in association with teething gels.
“Parents were also recommended to administer oral pain relievers and fever reducers, for 68.80% [of them], if necessary: in 94.30% of cases, they opted for Paracetamol.
“The best levels of parental satisfaction regarding the treatment’s effectiveness were reached when Camilia® and teething gels were associated, with an 85.50% satisfaction rate.
“When asked about their intention to use the product prescribed for future teething episodes, the answer was positive for 85.20% [of parents] in the case of Camilia® being used on its own. Positive responses dropped to 75.90% in cases where teething gels alone were used. Finally, positive answers reached a high of 86.90% in cases where Camilia® was administered in association with teething gels.
“The conclusion is clear: the study’s results highlight the fact that paediatricians have integrated homeopathic medicinal product Camilia® into their prescriptions, alone or in association with teething gels. Parents expressed satisfaction with the management provided by their paediatrician [of the infant’s teething problems].
“Homeopathy has been used for over 200 years. In France, homeopathic medicines are distributed and available in all pharmacies — i.e. in about 20,000 of them, all over the country. Patients are used to be prescribed homeopathic medicines. But they can also buy them directly, over the counter [OTC]. The pharmacists give advice about homeopathic medicine. Homeopathy is integrated into the practice of GPs.
“We hope this will also happen in the UK, as it represents a real plus in terms of public health.”
For further information, please contact :
Quote ref. : FTPB3851
Ms Katherine WOODS - Press Officer
UBIFRANCE Press Office in London
Tel: +44 (0) 207 024 3640
View other press releases at : http://www.ubifrance.com/uk/